Cytosorbents Crp (CTSO)vsEli Lilly and Company (LLY)
CTSO
Cytosorbents Crp
$0.57
-5.80%
HEALTHCARE · Cap: $38.95M
LLY
Eli Lilly and Company
$987.05
-0.18%
HEALTHCARE · Cap: $862.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 194836% more annual revenue ($72.25B vs $37.06M). LLY leads profitability with a 35.0% profit margin vs -22.1%. LLY earns a higher WallStSmart Score of 78/100 (B+).
CTSO
Avoid22
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.8% YoY
Areas to Watch
0.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -96.4% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 33.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CTSO
CTSO has a balanced fundamental profile.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : CTSO
The primary concerns for CTSO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
CTSO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
CTSO carries more volatility with a beta of 1.44 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 22/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytosorbents Crp
HEALTHCARE · MEDICAL DEVICES · USA
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?